WS Investor
29 Sep 2026, 19:25
Johnson & Johnson Highlights Two-Year IMAAVY Data Showing Sustained Disease Control in gMG
Johnson & Johnson reported new two-year data for IMAAVY in generalized myasthenia gravis, showing sustained improvements in daily function and muscle strength among adolescents treated in the Phase 2/3 Vibrance-MG long-term extension study.
At Week 108, patients with available data maintained a mean improvement of 2.88 points on the MG-ADL scale and 8.25 points on the QMG scale from baseline. Corticosteroid use also declined, with three of six adolescents on steroids at study entry reducing their dose and one discontinuing treatment after two years. No new safety signals were identified over the treatment period.
Johnson & Johnson also presented real-world survey data from healthcare professionals treating adults with anti-AChR or anti-MuSK antibody-positive gMG. Fluctuating symptom control was the most frequently cited reason for discontinuing a prior advanced therapy, while a consistent treatment schedule and expectations for improved efficacy were the main reasons for switching to IMAAVY.
Among 97 patients who transitioned to IMAAVY, healthcare professionals reported that 73.2% were “much improved” or “very much improved.” Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.
IMAAVY is an FcRn blocker approved for adults and patients aged 12 years and older with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis. The latest data strengthen Johnson & Johnson’s clinical case for the treatment by showing durability of response and potential steroid-sparing benefits across longer-term use.
Johnson & Johnson reported new two-year data for IMAAVY in generalized myasthenia gravis, showing sustained improvements in daily function and muscle strength among adolescents treated in the Phase 2/3 Vibrance-MG long-term extension study.
At Week 108, patients with available data maintained a mean improvement of 2.88 points on the MG-ADL scale and 8.25 points on the QMG scale from baseline. Corticosteroid use also declined, with three of six adolescents on steroids at study entry reducing their dose and one discontinuing treatment after two years. No new safety signals were identified over the treatment period.
Johnson & Johnson also presented real-world survey data from healthcare professionals treating adults with anti-AChR or anti-MuSK antibody-positive gMG. Fluctuating symptom control was the most frequently cited reason for discontinuing a prior advanced therapy, while a consistent treatment schedule and expectations for improved efficacy were the main reasons for switching to IMAAVY.
Among 97 patients who transitioned to IMAAVY, healthcare professionals reported that 73.2% were “much improved” or “very much improved.” Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.
IMAAVY is an FcRn blocker approved for adults and patients aged 12 years and older with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis. The latest data strengthen Johnson & Johnson’s clinical case for the treatment by showing durability of response and potential steroid-sparing benefits across longer-term use.
